Paper Details

  1. Home
  2. Paper Details

Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.

Author: AntoniucciDavid, BellandiBenedetta, CarrabbaNazario, GrasselliniSilvia, MiglioriniAngela, ParodiGuido, RamazzottiErica, ValentiRenato, VendittiFrancesco

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the bleeding rates and adherence to treatment in patients treated with prasugrel, a medication used to prevent blood clots. The study found that bleeding rates in real-world patients were comparable to those reported in clinical trials, and that minimal bleeding events did not appear to affect adherence to treatment.
Paper Details　
Original Abstract of the Article :
Recent guidelines have recommended the use of aspirin and prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. However, prasugrel use has been evaluated only in randomized trials. This study sought to evaluate bleeding rates and adherence to treatment in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.amjcard.2011.08.034

データ提供：米国国立医学図書館（NLM）

Prasugrel Therapy in Coronary Stent Implantation: A Real-World Assessment of Bleeding Rates and Adherence

This research takes a real-world look at prasugrel therapy, a medication commonly used in patients undergoing coronary stent implantation. Coronary stents are tiny mesh tubes implanted into arteries to keep them open, restoring blood flow to the heart. Prasugrel is a powerful medication that helps prevent blood clots from forming in the stent.

The study investigates the rates of bleeding events and patient adherence to prasugrel therapy in a large cohort of patients who underwent coronary stent implantation. The researchers analyzed data from a real-world setting, as opposed to the controlled environment of a clinical trial.

Bleeding Risks and Adherence: Real-World Insights

The findings reveal that bleeding event rates associated with prasugrel therapy in a real-world setting are comparable to those observed in clinical trials. However, the researchers found a higher rate of minor bleeding events, which did not seem to significantly impact patient adherence to the medication.

Navigating the Risks and Benefits

This study provides valuable insights into the real-world implications of prasugrel therapy. Just as a camel navigates the treacherous landscape of the desert, doctors and patients must carefully weigh the potential risks and benefits of this medication. It's essential to consider individual patient characteristics, such as age, weight, and medical history, to make informed decisions about treatment.

Dr.Camel's Conclusion

This study provides valuable real-world data on the use of prasugrel therapy for patients undergoing coronary stent implantation. While the bleeding event rates are generally comparable to those reported in clinical trials, it's essential to be aware of the potential risks and benefits of this medication. Individualized patient care and careful monitoring remain essential for ensuring the safety and effectiveness of treatment.

Date :
  1. Date Completed 2012-02-28
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

21996146

DOI: Digital Object Identifier

10.1016/j.amjcard.2011.08.034

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.